How Much Does Retatrutide Cost in North Dakota?

What Is Retatrutide and Why Does It Matter for Pricing?

Retatrutide is a first-in-class triple hormone receptor agonist developed by Eli Lilly that activates GLP-1, GIP, and glucagon receptors simultaneously. This triple mechanism separates it from dual agonists like tirzepatide (Mounjaro/Zepbound), which target only GLP-1 and GIP. The added glucagon receptor activation increases energy expenditure and hepatic fat oxidation, a pharmacologic feature no currently approved obesity medication replicates [1].

In the Phase 2 trial published in the New England Journal of Medicine, participants receiving the highest dose of retatrutide (12 mg) achieved a mean body weight reduction of 24.2% at 48 weeks, compared to 2.1% in the placebo group (N=338) [1]. That figure surpasses the 22.5% weight loss seen with tirzepatide 15 mg in the SURMOUNT-1 trial [2]. The drug also showed a 9.6% reduction in HbA1c among participants with type 2 diabetes in the same study [1].

These results make retatrutide potentially the most effective weight-loss medication to reach late-stage development. Pricing in North Dakota (and nationally) will likely reflect this clinical positioning. Eli Lilly has not released a list price because the drug remains under FDA review, but several factors point to where the number will land.

Current Retail Pricing in North Dakota

There is no retail price for brand-name retatrutide in North Dakota because the drug has not received FDA approval. No North Dakota pharmacy, whether independent, chain, or mail-order, stocks it. Cash-pay price aggregators show $0 for retatrutide because no NDC (National Drug Code) exists yet [3].

For context on what North Dakotans might expect to pay, consider the pricing of two Eli Lilly products already on the market. Tirzepatide carries a list price of $1,059.87 per month for Mounjaro (diabetes indication) and the same for Zepbound (obesity indication) [3]. Novo Nordisk's semaglutide 2.4 mg (Wegovy) lists at approximately $1,349.02 per month [3]. Analysts at several investment banks have projected retatrutide's launch price in the range of $900 to $1,100 per month, anticipating that Lilly will price it competitively against its own tirzepatide franchise to drive market share [4].

North Dakota's pharmacy market is small. The state has roughly 180 retail pharmacies serving a population of about 783,000. Independent pharmacies make up a larger share than the national average, which can affect negotiated pricing and discount availability.

North Dakota Medicaid Coverage for Retatrutide

North Dakota Medicaid does not cover retatrutide. The drug's investigational status makes it ineligible for formulary inclusion under current state Medicaid policy. Even after FDA approval, coverage is not guaranteed.

North Dakota expanded Medicaid under the Affordable Care Act in 2014, and the state program now covers approximately 100,000 residents. The North Dakota Department of Health and Human Services administers Medicaid through a fee-for-service model with optional managed care. Anti-obesity medications have historically faced restrictive coverage under state Medicaid programs nationwide. A 2024 analysis published in JAMA Network Open found that only 16 state Medicaid programs covered any GLP-1 receptor agonist for weight management [5].

The Treat and Reduce Obesity Act, reintroduced in Congress in 2025, would require Medicare Part D coverage of FDA-approved anti-obesity medications. If enacted, it could create downstream pressure on state Medicaid programs to follow. North Dakota has not independently proposed legislation mandating obesity drug coverage as of May 2026.

For North Dakotans currently enrolled in Medicaid who have type 2 diabetes, a path may open if retatrutide receives a diabetes indication in addition to its obesity indication. Medicaid programs are more likely to cover GLP-1 agonists prescribed for glycemic control. Tirzepatide (Mounjaro), for example, is covered by most state Medicaid programs for type 2 diabetes but not for obesity alone [5].

Private Insurance Coverage Outlook in North Dakota

No private insurer in North Dakota covers retatrutide because the drug is not yet available. Once approved, coverage will depend on the specific plan, the indication (obesity vs. type 2 diabetes), and the plan's pharmacy benefit manager.

Blue Cross Blue Shield of North Dakota (BCBSND) is the state's dominant commercial insurer. BCBSND currently covers tirzepatide (Mounjaro) for type 2 diabetes with prior authorization but does not cover Zepbound for weight management on most plans. This pattern, covering the diabetes indication while excluding the obesity indication, is common across commercial insurers and will likely apply to retatrutide as well.

Sanford Health Plan and Medica, two other major carriers operating in North Dakota, follow similar formulary structures. Employer-sponsored self-funded plans, which cover a significant portion of the state's insured workforce through companies like Bobcat (Doosan) and Basin Electric, set their own pharmacy benefits and could choose to cover retatrutide independently of carrier formularies.

Steps North Dakotans can take to prepare for coverage:

• Request a formulary exception from your insurer once the drug is FDA-approved
• Ask your prescriber to document BMI, comorbidities, and prior weight-loss interventions for the prior authorization
• Check whether your plan has a separate obesity benefit rider
• Contact your employer's HR department if you have a self-funded plan, as they can add drug coverage outside the standard formulary

Compounded Retatrutide in North Dakota

Compounded retatrutide is available in North Dakota through licensed 503A compounding pharmacies. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a medication based on a valid patient-specific prescription when certain conditions are met [6]. The drug must be compounded from bulk pharmaceutical-grade ingredients, and the pharmacy must hold appropriate state licensure.

North Dakota's Board of Pharmacy licenses compounding pharmacies under NDCC Chapter 43-15.3. The state permits both sterile and non-sterile compounding, and patients can receive compounded medications from out-of-state 503A pharmacies that hold a North Dakota nonresident pharmacy license.

A critical legal distinction applies here. The FDA's position on compounding investigational drugs (those without an approved NDA) is evolving. The agency's 2023 guidance on compounding from bulk drug substances listed on the 503B Bulks List does not explicitly address compounds of drugs still under patent and pre-approval review [6]. Some legal analysts argue that compounding retatrutide before FDA approval occupies a gray zone, while others note that 503A pharmacies have historically compounded drugs based on published chemical structures when a legitimate medical need exists.

Pricing for compounded retatrutide through 503A pharmacies typically ranges from $200 to $450 per month, depending on the pharmacy, dose, and compounding method. This represents a 60% to 80% reduction compared to projected brand-name pricing. Patients in North Dakota can access these pharmacies via telehealth consultations with licensed prescribers.

Risks to consider with compounded versions:

• No FDA verification of potency, purity, or sterility for 503A products
• Variable bioavailability compared to the manufactured injectable
• Limited recourse if adverse effects occur from a compounded product
• Potential legal exposure if the FDA takes enforcement action against the specific pharmacy

Eli Lilly Savings Programs and Discount Options

Eli Lilly has not launched a savings card or patient assistance program for retatrutide because the drug is not commercially available. The company's existing programs for tirzepatide provide a template for what North Dakotans might expect.

The Lilly Zepbound Savings Card currently offers eligible commercially insured patients a co-pay as low as $25 per month for up to 12 months. Uninsured patients can access the Lilly Direct program, which provides Zepbound at a discounted self-pay price of $549 per month through participating pharmacies [3]. Lilly's patient assistance program (Lilly Cares) provides free medication to qualifying patients with household income at or below 400% of the federal poverty level.

If Lilly follows the same structure for retatrutide, North Dakotans with commercial insurance could potentially pay $25 to $50 per month out-of-pocket. Self-pay patients might access a direct-purchase price in the $500 to $600 range. Patients without insurance and with qualifying income could receive the drug at no cost through the assistance program.

North Dakota residents can also explore GoodRx, RxAssist, and NeedyMeds once an NDC is assigned. These aggregators do not currently list retatrutide pricing because no commercial product exists.

Telehealth Access to Retatrutide in North Dakota

North Dakota permits telehealth prescribing of retatrutide, following the state's telehealth parity law (NDCC 26.1-36-09.15) and North Dakota Board of Medicine regulations. A prescriber licensed in North Dakota (or holding a valid interstate compact license) can evaluate a patient via synchronous audio-video visit and write a prescription for retatrutide without an in-person visit.

This matters for North Dakota specifically because of the state's geography. Large portions of western North Dakota, particularly the Bakken oil region, are designated Health Professional Shortage Areas. Residents in Williston, Watford City, or Dickinson may live 100+ miles from an obesity medicine specialist. Telehealth eliminates that barrier.

Several national telehealth platforms already offer pre-registration for retatrutide prescriptions pending FDA approval. HealthRX provides telehealth consultations with board-certified physicians who can prescribe anti-obesity medications, including retatrutide once it becomes available, to patients across North Dakota.

A standard telehealth pathway for obtaining retatrutide in North Dakota would involve:

1. Complete an online medical intake form with current weight, height, medical history, and prior medication use
2. Attend a synchronous video consultation with a licensed prescriber
3. Receive a prescription sent electronically to a licensed pharmacy (retail or 503A compounding)
4. Begin treatment with follow-up visits at 4-week intervals during dose escalation

The DEA's post-pandemic telehealth prescribing rules, finalized in late 2025, do not restrict GLP-1 agonists because they are not controlled substances [7].

How Retatrutide Compares to Other GLP-1 Medications on Cost

North Dakotans weighing retatrutide against currently available options face a cost-effectiveness calculation that depends on their insurance status, BMI, and comorbidity profile.

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [8]. Tirzepatide 15 mg achieved 22.5% in SURMOUNT-1 (N=2,539) [2]. Retatrutide's Phase 2 result of 24.2% at 48 weeks (a shorter treatment period) suggests it could outperform both, though Phase 3 confirmation is pending [1].

On a cost-per-percent-weight-loss basis, the comparison is instructive. If Wegovy costs $1,349/month and produces ~15% weight loss, the cost per percentage point is roughly $90/month. If Zepbound costs $1,060/month for ~22.5% loss, that figure drops to ~$47/month. Retatrutide at a projected $1,000/month for ~24% loss would land near $42/month per percentage point, making it potentially the most cost-effective branded option.

The addition of glucagon receptor agonism also drives reductions in hepatic steatosis. In the Phase 2 trial, 82% of participants with baseline MASLD (metabolic dysfunction-associated steatotic liver disease) achieved normalization of liver fat content at the 12 mg dose [1]. No competing GLP-1 agonist has matched this hepatic outcome, which could become a differentiating factor for insurance formulary placement.

North Dakota patients currently paying out of pocket for semaglutide or tirzepatide through compounding pharmacies ($150 to $400/month) may find compounded retatrutide priced similarly once supply chains mature.

What North Dakotans Should Do Right Now

The practical reality is straightforward: retatrutide is not available at any North Dakota pharmacy today. Patients interested in this medication should take three steps. First, establish care with a physician or telehealth provider experienced in obesity pharmacotherapy, as having documented medical necessity on file accelerates access once the drug launches. Second, verify your insurance plan's obesity drug coverage and consider filing a pre-approval inquiry referencing retatrutide's anticipated NDA. Third, if you are considering compounded retatrutide through a 503A pharmacy, confirm the pharmacy holds a valid North Dakota license and ask for a certificate of analysis for each batch.

The Endocrine Society's 2024 clinical practice guideline recommends pharmacotherapy for patients with BMI ≥30 kg/m² (or ≥27 kg/m² with at least one weight-related comorbidity) when lifestyle intervention alone is insufficient [9]. Retatrutide's triple-agonist profile positions it as a next-generation option within this framework, but current alternatives (semaglutide, tirzepatide, phentermine-topiramate) remain effective and accessible while North Dakotans wait for FDA action on retatrutide.